THE NEXT FRONTIER OF INDIAN PHARMA: BIOLOGICS AND ADVANCED THERAPEUTICS
TL;DR
The recent BioE3 policy and Biopharma SHAKTI initiative, with its Rs.10,000/- crore outlay signals a definitive pivot from volume driven growth to value driven innovations in the move to much needed affordable next generation biologics.
Abstract
Dear Reader, For decades the Indian Pharmaceutical Industry has proudly worn the mantle of the “Pharmacy of the World” driven by an unparalleled mastery of small molecules, using efficient manufacturing and chemical synthesis. However, as the global therapeutic landscape rapidly shifts to large molecules, precision biotherapeutics, cell and gene therapy we find ourselves at a critical inflection point. The year 2026 marks a significant milestone in Indian biopharma policy. The recent BioE3 policy and Biopharma SHAKTI initiative, with its Rs.10,000/- crore outlay signals a definitive pivot from volume driven growth to value driven innovations in the move to much needed affordable next generation biologics. The goal is to explicitly reduce import dependence, build shared clinical trial infrastructure and capture a significant share of the global biopharmaceutical market. While blockbuster biologics offer a massive window of opportunity, capitalizing on it requires more than manufacturing scale. It demands integration of advanced biologic technology, rigorous clinical evaluation and an end to end bio-manufacturing ecosystem.